COVID-19 and associations with frailty and multimorbidity: a prospective analysis of UK Biobank participants.


Journal

Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 08 06 2020
accepted: 07 07 2020
pubmed: 25 7 2020
medline: 2 10 2020
entrez: 25 7 2020
Statut: ppublish

Résumé

Frailty and multimorbidity have been suggested as risk factors for severe COVID-19 disease. We investigated, in the UK Biobank, whether frailty and multimorbidity were associated with risk of hospitalisation with COVID-19. 502,640 participants aged 40-69 years at baseline (54-79 years at COVID-19 testing) were recruited across UK during 2006-10. A modified assessment of frailty using Fried's classification was generated from baseline data. COVID-19 test results (England) were available for 16/03/2020-01/06/2020, mostly taken in hospital settings. Logistic regression was used to discern associations between frailty, multimorbidity and COVID-19 diagnoses, after adjusting for sex, age, BMI, ethnicity, education, smoking and number of comorbidity groupings, comparing COVID-19 positive, COVID-19 negative and non-tested groups. 4510 participants were tested for COVID-19 (positive = 1326, negative = 3184). 497,996 participants were not tested. Compared to the non-tested group, after adjustment, COVID-19 positive participants were more likely to be frail (OR = 1.4 [95%CI = 1.1, 1.8]), report slow walking speed (OR = 1.3 [1.1, 1.6]), report two or more falls in the past year (OR = 1.3 [1.0, 1.5]) and be multimorbid (≥ 4 comorbidity groupings vs 0-1: OR = 1.9 [1.5, 2.3]). However, similar strength of associations were apparent when comparing COVID-19 negative and non-tested groups. However, frailty and multimorbidity were not associated with COVID-19 diagnoses, when comparing COVID-19 positive and COVID-19 negative participants. Frailty and multimorbidity do not appear to aid risk stratification, in terms of positive versus negative results of COVID-19 testing. Investigation of the prognostic value of these markers for adverse clinical sequelae following COVID-19 disease is urgently needed.

Sections du résumé

BACKGROUND BACKGROUND
Frailty and multimorbidity have been suggested as risk factors for severe COVID-19 disease.
AIMS OBJECTIVE
We investigated, in the UK Biobank, whether frailty and multimorbidity were associated with risk of hospitalisation with COVID-19.
METHODS METHODS
502,640 participants aged 40-69 years at baseline (54-79 years at COVID-19 testing) were recruited across UK during 2006-10. A modified assessment of frailty using Fried's classification was generated from baseline data. COVID-19 test results (England) were available for 16/03/2020-01/06/2020, mostly taken in hospital settings. Logistic regression was used to discern associations between frailty, multimorbidity and COVID-19 diagnoses, after adjusting for sex, age, BMI, ethnicity, education, smoking and number of comorbidity groupings, comparing COVID-19 positive, COVID-19 negative and non-tested groups.
RESULTS RESULTS
4510 participants were tested for COVID-19 (positive = 1326, negative = 3184). 497,996 participants were not tested. Compared to the non-tested group, after adjustment, COVID-19 positive participants were more likely to be frail (OR = 1.4 [95%CI = 1.1, 1.8]), report slow walking speed (OR = 1.3 [1.1, 1.6]), report two or more falls in the past year (OR = 1.3 [1.0, 1.5]) and be multimorbid (≥ 4 comorbidity groupings vs 0-1: OR = 1.9 [1.5, 2.3]). However, similar strength of associations were apparent when comparing COVID-19 negative and non-tested groups. However, frailty and multimorbidity were not associated with COVID-19 diagnoses, when comparing COVID-19 positive and COVID-19 negative participants.
DISCUSSION AND CONCLUSIONS CONCLUSIONS
Frailty and multimorbidity do not appear to aid risk stratification, in terms of positive versus negative results of COVID-19 testing. Investigation of the prognostic value of these markers for adverse clinical sequelae following COVID-19 disease is urgently needed.

Identifiants

pubmed: 32705587
doi: 10.1007/s40520-020-01653-6
pii: 10.1007/s40520-020-01653-6
pmc: PMC7377312
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1897-1905

Subventions

Organisme : Medical Research Council
ID : MC_UP_A620_1015
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12011/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A620_1014
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585827
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585824
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400491
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585819
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 19583
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12011/2
Pays : United Kingdom
Organisme : Department of Health
ID : 10/33/04
Pays : United Kingdom

Références

Du Toit A (2020) Outbreak of a novel coronavirus. Nat Rev Microbiol 18:123–123. https://doi.org/10.1038/s41579-020-0332-0
doi: 10.1038/s41579-020-0332-0 pubmed: 31988490 pmcid: 7073251
World Health Organisation (2020) WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 . Accessed 25/05/20
World Health Organisation (2020) Coronavirus disease 2019 (COVID-19): situation report, 125. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200524-covid-19-sitrep-125.pdf . Accessed 25/05/20
Boddington N, Charlett A, Elgohari S et al. (2020) COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis. 10.1101/2020.05.18.20086157
Surveillances V (2020) The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly 2:113–122. https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003
doi: 10.3760/cma.j.issn.0254-6450.2020.02.003
CDC COVID-19 Response Team, Chow N, Fleming-Dutra K et al. (2020) Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. Morbidity and Mortality Weekly Report 69 :382. 10.15585/mmwr.mm6913e2
Nanda A, Vura NVRK, Gravenstein S (2020) COVID-19 in older adults. Aging Clin Exp Res 32:1199–1202. https://doi.org/10.1007/s40520-020-01581-5
doi: 10.1007/s40520-020-01581-5 pubmed: 32390064
Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323:1775–1776. https://doi.org/10.1001/jama.2020.4683
doi: 10.1001/jama.2020.4683 pubmed: 32203977
Abbatecola A, Antonelli-Incalzi R (2020) COVID-19 spiraling of frailty in older Italian patients. J Nutrition Health Aging 24:453–455. https://doi.org/10.1007/s12603-020-1357-9
doi: 10.1007/s12603-020-1357-9
Polidori MC, Maggi S, Mattace-Raso F et al (2020) The unavoidable costs of frailty: a geriatric perspective in the time of COVID-19. Geriatric Care. https://doi.org/10.4081/gc.2020.8989
doi: 10.4081/gc.2020.8989
Sinclair A, Abdelhafiz A (2020) Age, frailty and diabetes–triple jeopardy for vulnerability to COVID-19 infection. E Clin Med. https://doi.org/10.1016/j.eclinm.2020.100343
doi: 10.1016/j.eclinm.2020.100343
National Institute for Health and Care Excellence (2020) COVID-19 rapid guideline: critical care in adults: NICE guideline [NG159]. https://www.nice.org.uk/guidance/ng159 . Accessed 25/05/20
Roller-Wirnsberger R, Lindner S, Liew A et al (2020) European Collaborative and Interprofessional Capability Framework for Prevention and Management of Frailty-a consensus process supported by the Joint Action for Frailty Prevention (ADVANTAGE) and the European Geriatric Medicine Society (EuGMS). Aging Clin Exp Res 32:561–570. https://doi.org/10.1007/s40520-019-01455-5
doi: 10.1007/s40520-019-01455-5 pubmed: 31970670 pmcid: 7170812
Tay HS, Harwood R (2020) Atypical presentation of COVID-19 in a frail older person. Age Ageing. https://doi.org/10.1093/ageing/afaa068
doi: 10.1093/ageing/afaa068 pubmed: 32315386 pmcid: 7188159
Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol Series A Biolog Sci Med Sci 56:M146–M157. https://doi.org/10.1093/gerona/56.3.m146
doi: 10.1093/gerona/56.3.m146
Hanlon P, Nicholl BI, Jani BD et al (2018) Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health 3:e323–e332. https://doi.org/10.1016/S2468-2667(18)30091-4
doi: 10.1016/S2468-2667(18)30091-4 pubmed: 29908859 pmcid: 6028743
Ensrud KE, Ewing SK, Cawthon PM et al (2009) A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc 57:492–498. https://doi.org/10.1111/j.1532-5415.2009.02137.x
doi: 10.1111/j.1532-5415.2009.02137.x pubmed: 19245414 pmcid: 2861353
Kojima G (2015) Frailty as a predictor of future falls among community-dwelling older people: a systematic review and meta-analysis. J Am Med Direc Assoc 16:1027–1033. https://doi.org/10.1016/j.jamda.2015.06.018
doi: 10.1016/j.jamda.2015.06.018
Barnett K, Mercer SW, Norbury M et al (2012) Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380:37–43. https://doi.org/10.1016/S0140-6736(12)60240-2
doi: 10.1016/S0140-6736(12)60240-2 pubmed: 22579043
Nicholl BI, Mackay D, Cullen B et al (2014) Chronic multisite pain in major depression and bipolar disorder: cross-sectional study of 149,611 participants in UK Biobank. BMC Psychiatry 14:350. https://doi.org/10.1186/s12888-014-0350-4
doi: 10.1186/s12888-014-0350-4 pubmed: 25490859 pmcid: 4297369
Armstrong J, Rudkin JK, Allen N et al (2020) Dynamic linkage of COVID-19 test results between Public Health England’s Second Generation Surveillance System and UK Biobank. Microb Genom. https://doi.org/10.1099/mgen.0.000397
doi: 10.1099/mgen.0.000397 pubmed: 32553051 pmcid: 7478634
Office for National Statistics (2020) Coronavirus (COVID-19) Infection Survey pilot: England, 21 May 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/28may2020 . Accessed 25/05/20
Collard RM, Boter H, Schoevers RA et al (2012) Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc 60:1487–1492. https://doi.org/10.1111/j.1532-5415.2012.04054.x
doi: 10.1111/j.1532-5415.2012.04054.x pubmed: 22881367
Fang Y, Zhang H, Xie J et al (2020) Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. https://doi.org/10.1148/radiol.2020200432
doi: 10.1148/radiol.2020200432 pubmed: 32427559 pmcid: 7233473
Long C, Xu H, Shen Q et al (2020) Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. https://doi.org/10.1016/j.ejrad.2020.108961
doi: 10.1016/j.ejrad.2020.108961 pubmed: 32526669 pmcid: 7165099
Woolford S, Sohan O, Dennison E et al (2020) Approaches to the diagnosis and prevention of frailty. Aging Clin Exp Res. https://doi.org/10.1007/s40520-020-01559-3
doi: 10.1007/s40520-020-01559-3 pubmed: 32705587 pmcid: 7377312
Clegg A, Young J, Iliffe S et al (2013) Frailty in elderly people. Lancet 381:752–762. https://doi.org/10.1016/S0140-6736(12)62167-9
doi: 10.1016/S0140-6736(12)62167-9 pubmed: 23395245
Aiden H (2018) Multimorbidity: Understanding the Challenge. Richmond Group of Charities. https://www.richmondgroupofcharities.org.uk/sites/default/files/multimorbidity_-_understanding_the_challenge.pdf . Accessed 25/05/20
Vetrano DL, Palmer K, Marengoni A et al (2019) Frailty and multimorbidity: a systematic review and meta-analysis. J Gerontol 74:659–666. https://doi.org/10.1093/gerona/gly110
doi: 10.1093/gerona/gly110
National Institute for Health and Clinical Excellence (2016) Multimorbidity: clinical assessment and management: NICE guideline [NG56]. https://www.nice.org.uk/guidance/ng56 . Accessed 26/05/20
Nunes BP, Flores TR, Mielke GI et al (2016) Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 67:130–138. https://doi.org/10.1016/j.archger.2016.07.008
doi: 10.1016/j.archger.2016.07.008 pubmed: 27500661
Boreskie KF, Boreskie PE, Melady D (2020) Age is just a number–and so is frailty: Strategies to inform resource allocation during the COVID-19 pandemic. Canadian J Emerg Med. https://doi.org/10.1017/cem.2020.358
doi: 10.1017/cem.2020.358
Landi F, Barillaro C, Bellieni A et al (2020) The new challenge of geriatrics: saving frail older people from the Sars-COV-2 pandemic infection. J Nutrition Health Aging 24:466–470. https://doi.org/10.1007/s12603-020-1356-x
doi: 10.1007/s12603-020-1356-x
Public Health England (2020) Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19 . Accessed 26/05/20
Palmer K, Monaco A, Kivipelto M et al (2020) The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing. Aging Clin Exp Res 32:1189–1194. https://doi.org/10.1007/s40520-020-01601-4
doi: 10.1007/s40520-020-01601-4 pubmed: 32458356

Auteurs

S J Woolford (SJ)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.

S D'Angelo (S)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.

E M Curtis (EM)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.

C M Parsons (CM)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.

K A Ward (KA)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.

E M Dennison (EM)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.

H P Patel (HP)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
Medicine for Older People, University Hospital Southampton, Southampton, UK.
Academic Geriatric Medicine, University of Southampton, Southampton, UK.
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.

C Cooper (C)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.

N C Harvey (NC)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK. nch@mrc.soton.ac.uk.
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK. nch@mrc.soton.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH